Monte Rosa Therapeutics Files 8-K
Ticker: GLUE · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1826457
| Field | Detail |
|---|---|
| Company | Monte Rosa Therapeutics, Inc. (GLUE) |
| Form Type | 8-K |
| Filed Date | Jun 27, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
TL;DR
Monte Rosa filed a standard 8-K, no major news.
AI Summary
Monte Rosa Therapeutics, Inc. filed an 8-K on June 27, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This filing indicates routine corporate reporting by Monte Rosa Therapeutics, Inc. to the SEC, without disclosing new material information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would suggest an immediate change in risk.
Key Players & Entities
- Monte Rosa Therapeutics, Inc. (company) — Registrant
- June 27, 2024 (date) — Date of earliest event reported
FAQ
What is the purpose of this 8-K filing?
This 8-K filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Monte Rosa Therapeutics, Inc.
In which state was Monte Rosa Therapeutics, Inc. incorporated?
Monte Rosa Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address of Monte Rosa Therapeutics, Inc.?
The address of the principal executive offices is 321 Harrison Avenue, Suite 900, Boston, MA 02118.
What is the registrant's telephone number?
The registrant's telephone number is (617) 949-2643.
Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-06-27 07:04:27
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share GLUE The Nasdaq
Filing Documents
- glue-20240627.htm (8-K) — 43KB
- glue-ex99_1.htm (EX-99.1) — 28KB
- img106802192_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-078159.txt ( ) — 216KB
- glue-20240627.xsd (EX-101.SCH) — 30KB
- glue-20240627_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure On June 27, 2024, Monte Rosa Therapeutics, Inc. issued a press release titled "Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160". The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits 99.1 Press Release issued by Monte Rosa Therapeutics, Inc. dated June 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monte Rosa Therapeutics, Inc. Date: June 27, 2024 By: /s/ Markus Warmuth Markus Warmuth President and Chief Executive Officer